Expert insights. Personalized for you.
Bio Pharma Dive
DECEMBER 5, 2022
After a private equity takeover unraveled this summer, the women’s health company is selling its drug portfolio to Mayne Pharma in a $153 million deal
The FDA Law Blog
DECEMBER 5, 2022
By Douglas B. Farquhar & John W.M.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Phorum
DECEMBER 4, 2022
Clinical trials of a wireless brain chip developed by Elon Muck’s Neuralink company will be tested in human volunteers within the next six months – and Musk himself says he intends to have one implanted for a future demo event.
The Pharma Data
DECEMBER 6, 2022
Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy. Novartis.
Advertiser: FourKites
Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.
Bio Pharma Dive
DECEMBER 6, 2022
The second startup to emerge from Star’s “hub-and-spoke” model aims to develop a Hemlibra-like antibody drug for the blood clotting disorder von Willebrand disease
Fierce Pharma
DECEMBER 7, 2022
GSK, Sanofi, Pfizer and Boehringer Ingelheim free from federal Zantac litigation with new ruling. zbecker. Wed, 12/07/2022 - 10:05
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioPharma Reporter
DECEMBER 6, 2022
Global pharma giants, GSK, Sanofi, and Takeda, are set to collaborate with Singapore researchers to boost innovation in local biologics and vaccines manufacturing. Markets & Regulations
Bio Pharma Dive
DECEMBER 5, 2022
The positive results could help Novartis secure approval for earlier use of the radiopharmaceutical drug Pluvicto, potentially broadening the number of eligible patients by several times the current market
The Pharma Data
DECEMBER 6, 2022
Novartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer.
Speaker: Steve Goldstein, Sales Leader
Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.
BioSpace
DECEMBER 4, 2022
Whether a job search is voluntary or not, the psychological toll of months of interviews, wrangling over pay and benefits and evaluating options has a weighty psychological toll
Bio Pharma Dive
DECEMBER 5, 2022
The pandemic shined a light on the importance of diversity in clinical trials. Syneos Health can help your team devise a diversity strategy
Pharmaceutical Technology
DECEMBER 5, 2022
Sanofi has signed an agreement with the Queensland Government in Australia to establish a $190m (A$280m) research facility in Brisbane. With the establishment of this Translational Science Hub, Queensland is set to become an international messenger ribonucleic acid (mRNA) vaccine hub.
Pharma Phorum
DECEMBER 4, 2022
Contrary to Big Tech, historically the pharmaceutical industry has had a good reputation for being a female-positive industry. However, both industries share a common problem: failure to provide women with C-suite opportunities.
Advertiser: Aggregage
The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.
Fierce Pharma
DECEMBER 5, 2022
SABCS: Lilly aims Verzenio at broader post-surgery breast cancer nod as Novartis' rival draws near. Will FDA bite? Mon, 12/05/2022 - 15:10
Bio Pharma Dive
DECEMBER 5, 2022
Maria-Cruz Morillo, global therapeutic operations lead for rare diseases at Allucent, discusses the unique challenges of rare disease drug development and how the right expertise can help
Drug Channels
DECEMBER 6, 2022
In Preferred Pharmacy Networks in 2023’s Medicare Part D Plans: Cigna, CVS Health, Humana, UnitedHealthcare, WellCare, and More , I highlighted how those networks have taken over the world of stand-alone Medicare Part D prescription drug plans (PDP) and become a major presence in Medicare Advantage prescription drug (MA-PD) plans.
Pharma Phorum
DECEMBER 5, 2022
Valneva has moved a step closer to its goal of becoming the first company to file for approval of a vaccine against chikungunya virus in the US after reporting new clinical data today.
Fierce Pharma
DECEMBER 5, 2022
AstraZeneca partner FibroGen slaps former employees with trade secret theft lawsuit. zbecker. Mon, 12/05/2022 - 10:31
Bio Pharma Dive
DECEMBER 5, 2022
When Talisa Puentes-Ortega got the chance to advance her career by going back to school, Regis provided more than an environmental biology degree — it was the foundation of a community that continues to support her
Pharmaceutical Commerce
DECEMBER 7, 2022
Confirms cold chain company’s sustainability commitment.
Pharma Phorum
DECEMBER 5, 2022
Harnessing the power of natural killer (NK) cells to attack cancer is as-yet an unproven strategy in oncology – but one that is garnering increased interest as clinical trials start to generate data.
Eversana Intouch
DECEMBER 7, 2022
Justin Chase, SVP, Media, EVERSANA INTOUCH, was recently interviewed by Endpoints News for an article on how pharmaceutical companies are handling both paid and organic interaction on Twitter in the era of Elon Musk ownership.
Bio Pharma Dive
DECEMBER 6, 2022
In an interview with BioPharma Dive, the longtime industry executive discussed becoming a biotech investor and his plans for Abio-X, a new incubator with $150 million to spend on startups
Pharmaceutical Commerce
DECEMBER 7, 2022
Big Pharma to collaborate with researchers from A*STAR, along with Singapore universities.
The FDA Law Blog
DECEMBER 7, 2022
By Mark A. Tobolowsky & James E.
XTalks
DECEMBER 5, 2022
Clinical-stage biotech company PureTech Health has announced it has developed a new oral CBD therapeutic candidate with improved bioavailability and tolerability, which could expand use of the CBD prodrug in a wide range of indications and age groups.
Bio Pharma Dive
DECEMBER 7, 2022
The large cardiovascular outcomes trial is a major test for Esperion, which has struggled to sell its drug Nexletol since winning U.S. approval in 2020
Pharmaceutical Technology
DECEMBER 5, 2022
Cannabinoid receptors are a popular therapeutic target for cannabinoid-based drugs in the treatment of pain, neurological disorders and inflammation, according to GlobalData’s Pharma Intelligence Centre Drugs database.
BioPharma Reporter
DECEMBER 6, 2022
Curamys, a South Korean biotech developing cell and gene therapy using cell fusion technology to treat rare intractable diseases, has signed a strategic platform licensing agreement with US tech developer, MaxCyte. Markets & Regulations
Pharma Phorum
DECEMBER 5, 2022
A digital health assistant that can help people at risk of becoming dependent on alcohol has been launched in Belize, its first country, by the World Health Organisation (WHO) and Pan-American Health Organisation (PAHO).
Bio Pharma Dive
DECEMBER 6, 2022
Entact Bio aims to develop medicines that can enhance helpful proteins, rather than block harmful ones, a twist on the usual drugmaking playbook
BioSpace
DECEMBER 4, 2022
Monday, Verve Therapeutics revealed that the FDA has officially requested several buckets of additional safety information to lift the hold on its lead candidate, VERVE-101
Fierce Pharma
DECEMBER 5, 2022
In free fall, Clovis defaults on loan and agrees to further restrict Rubraca use. kdunleavy. Mon, 12/05/2022 - 09:34
263 
Let's personalize your content